Organon & Co. (NYSE:OGN) Stock Position Decreased by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI cut its stake in shares of Organon & Co. (NYSE:OGNFree Report) by 12.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,291 shares of the company’s stock after selling 1,713 shares during the quarter. Parsons Capital Management Inc. RI’s holdings in Organon & Co. were worth $177,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Wellington Shields Capital Management LLC bought a new stake in shares of Organon & Co. during the 4th quarter worth $27,000. Harvest Fund Management Co. Ltd boosted its stake in shares of Organon & Co. by 495.5% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock worth $28,000 after acquiring an additional 1,333 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at $35,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Organon & Co. by 97.7% in the third quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock valued at $39,000 after purchasing an additional 1,110 shares in the last quarter. Finally, Clear Street Markets LLC boosted its position in shares of Organon & Co. by 588.9% in the third quarter. Clear Street Markets LLC now owns 2,294 shares of the company’s stock worth $40,000 after buying an additional 1,961 shares during the period. 77.43% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upped their price target on Organon & Co. from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, February 20th.

Check Out Our Latest Report on Organon & Co.

Insider Buying and Selling at Organon & Co.

In other news, insider Kirke Weaver purchased 2,720 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average price of $18.36 per share, with a total value of $49,939.20. Following the purchase, the insider now owns 15,181 shares in the company, valued at approximately $278,723.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.17% of the company’s stock.

Organon & Co. Price Performance

NYSE:OGN opened at $17.91 on Thursday. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79. The stock’s 50-day moving average is $17.72 and its two-hundred day moving average is $15.61. The stock has a market cap of $4.58 billion, a PE ratio of 4.48, a price-to-earnings-growth ratio of 0.86 and a beta of 0.83.

Organon & Co. (NYSE:OGNGet Free Report) last released its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.14. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.55 billion. On average, equities research analysts anticipate that Organon & Co. will post 4.08 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Shareholders of record on Monday, February 26th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.12 annualized dividend and a yield of 6.25%. Organon & Co.’s dividend payout ratio (DPR) is presently 28.00%.

About Organon & Co.

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Read More

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.